Integra LifeSciences Holdings (IART) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Integra LifeSciences Holdings $16.50, price $15.53, upside +6.3%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Integra LifeSciences Holdings for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $8.90 – $76.19 · fair‑value band $6.60 – $26.41 · the $15.53 price screens below the $16.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Integra LifeSciences in your weekly email
Every Wednesday you see whether Integra LifeSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Show more
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Stock analysis
Integra LifeSciences Holdings (IART) currently trades at $15.53, while our model-based Fair Value estimate is $16.50, implying the stock looks roughly 5.9% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 5 models at a data quality of 95/100, which puts the evidence level at medium.
Scenario range: $6.60 (bear) to $26.41 (bull), the price of $15.53 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Integra LifeSciences Holdings reported revenue of $1.6B in FY2025 versus $1.5B in FY2021, a compound +1.5%/yr. Reported net income was −$516M in FY2025.
Key figures
Market cap $1.4B · P/S ratio 0.83 · EPS (TTM) $−6.47 · Net margin −31.6% · Return on equity −38.6% · Return on assets (EBIT) 3.4% · Operating margin 10.4% · Revenue (TTM) $1.6B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 6%, IART screens cheaper than that median.
Fair Value models
Bear $6.60Fair Value $16.50Bull $26.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2020 (pandemic). Over 10 years: +6.4% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.2% (2019) → 1.8% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Integra LifeSciences Holdings with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+6% · Above median
Profitability
Return on assets3% · Above median
Net margin (TTM)−30% · Bottom 25%
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth2% · Below median
Balance sheet
Debt / equity1.66× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.31× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Integra LifeSciences Holdings (IART) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $16.50 versus a price of $15.53, about +6% upside (fairly valued).
What is the fair value of IART?
Our model-based fair value for Integra LifeSciences Holdings is $16.50 (as of Sep 23, 2026), built from audited fundamentals. The current price: $15.53.
What is the quality score of IART?
Integra LifeSciences Holdings has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integra LifeSciences Holdings (IART)?
Our model-based price target is the fair value of $16.50 (as of Sep 23, 2026) from 2 valuation models. Cautious scenario $6.60, optimistic scenario $26.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Integra LifeSciences Holdings stock forecast for 2026?
Our models put fair value at $16.50, about +6% upside versus a price of $15.53 (fairly valued). Cautious scenario $6.60, optimistic scenario $26.41. The calculation is refreshed regularly with new filings.
What is the revenue of Integra LifeSciences Holdings (IART)?
Integra LifeSciences Holdings reported trailing-twelve-month revenue of about $1.6B (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Integra LifeSciences Holdings (IART)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integra LifeSciences Holdings it is $16.50 per share (as of Sep 23, 2026), against a price of $15.53. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Integra LifeSciences Holdings stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IART trades below its calculated fair value: price $15.53, fair value $16.50, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IART?
No. The price is what the market pays today ($15.53); the fair value is what the company's own numbers justify ($16.50). For Integra LifeSciences Holdings the two are $0.9700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integra LifeSciences Holdings worth?
The market values Integra LifeSciences Holdings at about $1.4B (market capitalisation, as of Sep 23, 2026). Per share that is $15.53; our models calculate a fair value of $16.50 per share.
What do the bullish and bearish scenarios say about IART?
Our models span a range for Integra LifeSciences Holdings: cautious scenario $6.60, base $16.50, optimistic $26.41 per share (as of Sep 23, 2026, price $15.53). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of IART?
The PEG ratio of Integra LifeSciences Holdings is 0.71 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Integra LifeSciences Holdings (IART)?
Balance-sheet figures for Integra LifeSciences Holdings (as of Sep 23, 2026): return on equity −38.6%, debt of 1.66 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is IART from its 52-week high?
Integra LifeSciences Holdings trades at $15.53, about 22% below its 52-week high of $19.85 and 74% above the low of $8.90 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $16.50 is for.
Which stocks are comparable to Integra LifeSciences Holdings?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integra LifeSciences Holdings stock attractive at the current price?
The data as of Sep 23, 2026: price $15.53, calculated fair value $16.50 (+6%), Quality Score 39/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IART calculated?
We run Integra LifeSciences Holdings through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $16.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Integra LifeSciences Holdings currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integra LifeSciences Holdings (IART)?
The closing price on Sep 23, 2026 was $15.53. Our model-based fair value is $16.50, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integra LifeSciences Holdings right now?
The model range is unusually wide ($6.60 to $26.41). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of Integra LifeSciences Holdings
How large is the market capitalisation of Integra LifeSciences Holdings (IART)?
The market capitalisation of Integra LifeSciences Holdings is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integra LifeSciences Holdings (IART)?
The price-to-sales ratio of Integra LifeSciences Holdings is 0.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integra LifeSciences Holdings (IART)?
Earnings per share at Integra LifeSciences Holdings are $−6.47. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Integra LifeSciences Holdings (IART)?
The net margin of Integra LifeSciences Holdings is −31.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integra LifeSciences Holdings (IART)?
The return on equity (ROE) of Integra LifeSciences Holdings is −38.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integra LifeSciences Holdings (IART)?
On an EBIT basis the return on assets of Integra LifeSciences Holdings is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Integra LifeSciences Holdings (IART)?
The operating margin of Integra LifeSciences Holdings is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Integra LifeSciences Holdings (IART)?
Revenue at Integra LifeSciences Holdings is growing +2.4% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integra LifeSciences Holdings (IART)?
Earnings per share at Integra LifeSciences Holdings are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Integra LifeSciences Holdings (IART) generate?
The free cash flow of Integra LifeSciences Holdings is −$45.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Integra LifeSciences Holdings (IART) carry?
The net debt of Integra LifeSciences Holdings is $1.8B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Integra LifeSciences Holdings in the live analysis
One click puts Integra LifeSciences Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026